Expensive ($500-$2,000 per scan) limiting serial monitoring
[DOI] [PMC free article] [PubMed] [Google Scholar] 205.Nobs S.P., Kolodziejczyk A.A., Adler L., Horesh N., Botscharnikow C., Herzog E., Mohapatra G., Hejndorf S., Hodgetts R.J., Spivak I., et al
However, our regulations do not address the impact of a third party intermediary's action or inaction resulting in failure to submit the MIPS eligible clinician's data as required, over which the MIPS eligible clinician has little to no control, on a MIPS eligible clinician's final score
(2) For a single source drug, excluding biosimilar biological products (both as defined in 414.902) (i) In circumstances in which negative or zero manufacturer's ASP data is reported for one or more, but not all, NDCs associated with a billing and payment code for that drug for a given quarter, the payment limit for the given quarter is calculated using only NDCs for that drug with positive manufacturer's ASP data